JNJ vs. SNY: Johnson & Johnson vs. Sanofi Stock Comparison
How do Johnson & Johnson (JNJ) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Johnson & Johnson (JNJ) and Sanofi (SNY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Johnson & Johnson (JNJ) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | JNJ | SNY |
|---|---|---|
| Name | Johnson & Johnson | Sanofi ADR |
| Country/Region | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 664.95 billion USD | 112.71 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | January 2, 1962 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JNJ | SNY |
|---|---|---|
| Total Return (1Y) | 53.82% | 2.73% |
| Total Return (3Y, Annualized) | 27.51% | 6.89% |
| Total Return (5Y, Annualized) | 14.71% | 3.16% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | JNJ | SNY |
|---|---|---|
| Volatility (1Y, Annualized) | 21.23% | 23.60% |
| Beta (5Y) | 0.21 | 0.28 |
| Max Drawdown (5Y) | -18.41% | -33.52% |
| Avg. Volume (3M) | 6.93M | 3.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JNJ | SNY |
|---|---|---|
| Sharpe Ratio (1Y) | 2.33 | -0.07 |
| Sortino Ratio (1Y) | 3.66 | -0.10 |
Profitability
ROE (TTM)
Johnson & Johnson (JNJ) at 20.02% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for JNJ.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 109.18%
- JNJ
- 20.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.72%
- Max
- 109.18%
- Q3
- 6.23%
- SNY
- 5.72%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Johnson & Johnson (JNJ) at 16.20% and Sanofi (SNY) at 8.20% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.20%
- Max
- 18.05%
- JNJ
- 16.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20%
- Max
- 18.05%
- SNY
- 8.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Johnson & Johnson (JNJ) at 25.74% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.74%
- Max
- 83.12%
- JNJ
- 25.74%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.89%
- Max
- 83.12%
- SNY
- 30.89%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JNJ | SNY |
|---|---|---|
| ROE (TTM) | 20.02% | 5.72% |
| ROA (TTM) | 8.46% | 5.31% |
| Net Margin (TTM) | 16.20% | 8.20% |
| Operating Margin (TTM) | 25.74% | 30.89% |
| Gross Margin (TTM) | 67.78% | 73.68% |
Growth
Revenue Growth
Both Johnson & Johnson (JNJ) at 6.05% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while Sanofi (SNY) at 39.43% is closer to the peer norm — faster per-share earnings growth for JNJ.
Growth Metrics
| Metric | JNJ | SNY |
|---|---|---|
| Revenue Growth (YoY) | 6.05% | 5.49% |
| Revenue Growth (3Y CAGR) | 5.60% | 4.82% |
| EPS Growth (YoY) | 90.50% | 39.43% |
| EPS Growth (3Y CAGR) | 17.90% | 6.02% |
Financial Strength
Current Ratio (MRQ)
Both Johnson & Johnson (JNJ) at 1.02 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.02
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JNJ
- 1.02
- Min
- 0.10
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- SNY
- 1.12
- Min
- 0.10
Debt / Equity (MRQ)
Both Johnson & Johnson (JNJ) at 0.55 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.55
- Max
- 1.42
- Q3
- 0.65
- JNJ
- 0.55
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27
- Max
- 1.42
- Q3
- 0.65
- SNY
- 0.27
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | JNJ | SNY |
|---|---|---|
| Current Ratio (MRQ) | 1.02 | 1.12 |
| Debt / Equity (MRQ) | 0.55 | 0.27 |
| Net Debt / EBITDA | 0.79 | 0.96 |
Dividends
Dividend Yield (TTM)
Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94%
- JNJ
- 1.94%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Johnson & Johnson (JNJ) reports 80.12%, ranking against industry peers normally.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
80.12%
- JNJ
- 80.12%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
119.86%
- SNY
- 119.86%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JNJ | SNY |
|---|---|---|
| Dividend Yield (TTM) | 1.94% | 0.00% |
| Dividend Payout Ratio (TTM) | 80.12% | 119.86% |
Valuation
P/E Ratio (TTM)
Both Johnson & Johnson (JNJ) at 41.92 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.92
- Max
- 85.34
- Q3
- 43.46
- JNJ
- 41.92
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.40
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- SNY
- 23.40
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.69 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JNJ
- 6.69
- Q1
- 3.01
- Min
- 0.01
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.21
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- SNY
- 2.21
- Min
- 0.01
P/B Ratio (MRQ)
Sanofi (SNY) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Johnson & Johnson (JNJ) at 8.16 carries a premium in the upper quartile — a clear price-to-book gap.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 13.53
- JNJ
- 8.16
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- SNY
- 1.38
- Min
- -5.59
Valuation Metrics
| Metric | JNJ | SNY |
|---|---|---|
| P/E Ratio (TTM) | 41.92 | 23.40 |
| P/S Ratio (TTM) | 6.69 | 2.21 |
| P/B Ratio (MRQ) | 8.16 | 1.38 |
| Free Cash Flow Yield (TTM) | 2.78% | 7.17% |